IDSA Survey Outcomes Important to Lyme Disease Patients

Real Lives/Real Stories

Severity of chronic Lyme disease (CLD) compared to other chronic conditions

In 2015, the Infectious Diseases Society of America opened comments for its proposed Lyme disease guideline revision process. Although the Institute of Medicine standards on creating trustworthy guidelines, requires that those affected by guidelines be included in the process, the IDSA proposed panel did not include a Lyme disease patient.

On March 24, 2015 launched a study focusing on outcomes Lyme disease patients value. Over 6,000 people responded. This study was the first to report not only quantitative responses, such as the percentage of patients initially misdiagnosed, but also individual open response comments by patients.

LDo presented the results of the study, which drew over 6,000 responses in one month, to the IDSA as part of the comments that it filed together with the national Lyme Disease Association on behalf of over 63 Lyme disease patient advocacy groups in the United States. View Comments To IDSA

The report on this study consists of two parts.

  • The first part of the report is called Real Lives/Real Stories – View Report
  • The second part is reflected in the chart book – View Chartbook
Key Points

Key points from the survey regarding the guidelines revisions follow.
Over 85% of patients believed that:

  • Both the ILADS and IDSA viewpoints should be reflected in treatment guidelines,
  • Treatment guidelines should inform patients regarding the uncertainty about treating persisting symptoms,
  • Patients should be informed about the risks and benefits of both treating and not treating Lyme disease,
  • Treatment guidelines should provide treatment options, allow the exercise of clinical judgment, provide for individualized treatment, and provide for a “patient-based” risk/benefit assessment,
  • Treatment guidelines should provide patients with the option to treat a potential infection to cure and provide for informed choice.

Study Highlights

  • treatment

    87% believe that obtaining higher rates of success in the treatment of early Lyme disease is critically important.

  • option to be tested

    82% believe that it is critically important that patients be given the option to be tested for Lyme disease even if they live in a state where Lyme disease is not regarded as common.

  • delays

    47% reported that they had had testing delayed or denied because it was not considered common in their state. 60% reported that their diagnosis was delayed on this basis. 69% reported the delay in diagnosis was more than a year.

  • symptoms

    60% reported that the intensity of their symptoms was severe or very severe.


MyLymeData Video

Click on the image below to view MyLymeData video.

CONTACT  |  MyLymeData  |  PRIVACY

Copyright © 2023. All Rights Reserved Site design by CauseRoar